A phase I, randomized, double-blinded, placebo-and moxifloxacin-controlled, four-period crossover study to evaluate the effect of gepotidacin on cardiac conduction as assessed by 12-lead electrocardiogram in healthy volunteers

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 5, 2017, Pages

  Hossain, Mohammad ^a   Zhou, Meijian ^c   Tiffany, Courtney ^a   Dumont, Etienne ^a   Darpo, Borje ^b,c  

^a GLAXOSMITHKLINE   (United States)

^b DANDERYD HOSPITAL   (Sweden)

^c ICardiac Technologies   (United States)

Author keywords

Cardiac safety; Healthy subjects; QT Prolongation; QTc; Thorough QT study

Indexed keywords

GEPOTIDACIN; MOXIFLOXACIN; PLACEBO; ACENAPHTHENE DERIVATIVE; ANTIINFECTIVE AGENT; FUSED HETEROCYCLIC RINGS; HETEROCYCLIC COMPOUND; QUINOLONE DERIVATIVE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; HEART CONDUCTION; HEART RATE; HUMAN; HUMAN EXPERIMENT; HYPERSALIVATION; MALE; MAXIMUM PLASMA CONCENTRATION; MOUTH DISEASE; NAUSEA; NORMAL HUMAN; OROPHARYNGEAL DISCOMFORT; PHARYNX DISEASE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QT PROLONGATION; QTC INTERVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROAT TIGHTNESS; VOMITING; ADOLESCENT; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; ELECTROCARDIOGRAPHY; LONG QT SYNDROME; MIDDLE AGED; YOUNG ADULT;

ACENAPHTHENES; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; FLUOROQUINOLONES; HEALTHY VOLUNTEERS; HEART RATE; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 85018185514     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02385-16     Document Type: Article

References (13)

1. ICH. 2005. ICH harmonized tripartite guideline E14. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. ICH, Geneva, Switzerland. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E14/E14-Guideline.pdf.
2. ICH. 2015. ICH E14 guideline: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Questions & answers (R3). ICH, Geneva, Switzerland. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E14/E14-Q-As-R3-Step4.pdf.
3. Tiffany CA, Hossain M, McDonald M. 2014. Safety and pharmacokinetics of single escalating IV doses of GSK2140944, a novel bacterial topoisomerase inhibitor. Abstr 54th Int Conf Antimicrob Agents Chemother, abstr 2611.
4. Fridericia LS. 1920. Die systolendauer im elektrokardiogramm bei normalen menchen und bei herzkranken. Acta Med Scand 53: 469-486.
5. Bazett HC. 1920. An analysis of time relations of electrocardiograms. Heart 7:353-367.
6. Tornoe CW, Garnett CE, Wang Y, Florian J, Li M, Gobburu JV. 2011. Creation of a knowledge management system for QT analyses. J Clin Pharmacol 51:1035-1042. https://doi.org/10.1177/0091270010378408.
7. Florian JA, Tornoe CW, Brundage R, Parekh A, Garnett CE. 2011. Population pharmacokinetic and concentration-QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies. J Clin Pharmacol 51: 1152-1162. https://doi.org/10.1177/0091270010381498.
8. Bloomfield D, Kost J, Ghosh K, Hreniuk D, Hickey L, Guitierrez M, Gottesdiener K, Wagner J. 2008. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther 84:475-480. https://doi.org/10.1038/clpt.2008.33.
9. Mason JW, Florian JA, Jr, Garnett CE, Moon TE, Selness DS, Spaulding RR. 2010. Pharmacokinetics and pharmacodynamics of three moxifloxacin dosage forms: implications for blinding in active-controlled cardiac repolarization studies. J Clin Pharmacol 50:1249-1259. https://doi.org/10.1177/0091270009356298.
10. Zhang J, Chen H, Tsong Y, Stockbridge N. 2015. Lessons learned from hundreds of thorough QT studies. Ther Innov Reg Sci 49:392-397.
11. Woosley RL, Romero KA. 2006. Drugs that prolong the QT interval, and/or induce torsades de pointes ventricular arrhythmia. Credible Medicines, Oro Valley, AZ. https://www.crediblemeds.org/healthcareproviders/.
12. Darpo B, Fossa AA, Couderc JP, Zhou M, Schreyer A, Ticktin M, Zapesochny A. 2011. Improving the precision of QT measurements. Cardiol J 18:401-410.
13. Hochberg Y, Benjamini Y. 1990. More powerful procedures for multiple significance testing. Stat Med 9:811-818. https://doi.org/10.1002/sim.4780090710.